Tamoxifen and secondary tumours. An update

Drug Safety

Volumn 16, Issue 2, 1997, Pages 104-117

  Wilking, Nils ^a   Isaksson, Erika ^a   Von Schoultz, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; ESTRADIOL; TAMOXIFEN;

ACUTE LEUKEMIA; ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DNA ADDUCT; DNA DAMAGE; DRUG MECHANISM; DRUG USE; ENDOMETRIUM CARCINOMA; ESTRADIOL BLOOD LEVEL; HUMAN; LIVER CANCER; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK; STOMACH CARCINOMA;

EID: 0031059677     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716020-00003     Document Type: Review

References (151)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 2. Lancet 1992; 339: 71-85
2. Degenshein GA, Bloom N, Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1980; 46: 2789-93
3. Dodds EC, Goldberg L, Lawson W, et al. Oestrogenic activity of certain synthetic compounds. Nature 1948; 141: 247-8
4. Legha SS, Carter SK. Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 1976; 3: 205-16
5. Rose C, Theilade K, Boesen E, et al. Treatment of advanced breast cancer with tamoxifen. Breast Cancer Res Treat 1982; 2: 395-400
6. Mouridsen H, Palshof T, Patterson J, et al. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978; 5: 131-41
7. Ingle JN, Mailliard JA, Schaid DJ, et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. Cancer 1991; 68: 34-9
8. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978; 38: 4289-91
9. Vollenweider-Zerargui L, Barrelet L, Wong Y, et al. The predictive value of estrogen and progesterone receptors concentrations on the clinical behaviour of breast cancer in women. Cancer 1986; 7: 1171-80
10. Fornander T, Cedermark B, Mattsson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-20
11. Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990; 26: 680-4
12. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst; 86: 527-37
13. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995; 59: 186-90
14. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-4
15. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991; 303: 435-7
16. Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398-406
17. Borgna J-L, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 1981; 256: 859-68
18. Jordan VC, Dix CJ, Rowsby L, et al. Studies on the mechanism of action of the non-steroidal antiestrogen tamoxifen (ICI 46.474) in the rat. Mol Cell Endocrinol 1977; 7: 177-92
19. Lau CK, Subramaniam M, Rasmussen K, et al. Rapid induction of the c-protooncogene in the avian oviduct by the antiestrogen tamoxifen. Proc Natl Acad Sci USA 1981; 88: 829-33
20. Webster NJG, Green S, Jin JR, et al. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988; 54: 199-207
21. Lønning PE, Lien EA. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol 1995; 21: 158-93
22. Berry M, Meztger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990; 9 (9): 2811-8
23. Parker MG. Action of 'pure' antiestrogens in inhibiting estrogen receptor action. Br J Cancer Res Treat 1993; 26: 131-7
24. Jordan VC, Collins MM, Rowsby L, et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977; 75; 305-16
25. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205
26. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984; 36: 245-76
27. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990; 11: 578-610
28. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 236: 852-6
29. Wilking N, Carlström K, Gustafsson S, et al. Oestrogen receptors and metabolism of oestrone sulphate in human mammary carcinoma. Eur J Cancer 1980; 16: 1339-44
30. Santner SJ, Feil PD, Santen RJ. In situ estrogen production via estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 1984; 59: 29-33
31. Gelly C, Pasqualini JR. Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone sulfate to estradiol in the R-27 cells, a tamoxifen-resistant line derived from MCF-7 human breast cancer cells. J Steroid Biochem 1988; 30: 321-4
32. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumour agents. Endocrine Rev 1990; 11: 578-610
33. Noguchi S, Motomura K, Inaji H, et al. Down-regulation of transforming growth-factor-alpha by tamoxifen in human breast cancer. Cancer 1993; 72: 131-6
34. Thomp AM, Kerr DJ, Steel CM. Transforming growth factor β1 is implicated in failure of tamoxifen therapy in human breast cancer. Br J Cancer 1991; 63: 609-14
35. Lipton A, Morris ID. Calcium antagonism by the antiestrogen tamoxifen. Cancer Chemother Pharmacol 1986; 18: 17-20
36. Boccardo F, Guarneri D, Rubagotti A, et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984; 70: 61-8
37. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985; 69: 237-8
38. Stewart HJ, Knight GM. Tamoxifen and the uterus and endometrium [letter]. Lancet 1989; 1: 616
39. Ribeiro G, Swindell R. The Christie hospital adjuvant tamoxifen trial: status at 10 years. Br J Cancer 1988; 57: 601-3
40. van Leeuwen FE, Benreadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-52
41. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013-7
42. Bocklage T, Lee KR, Belinson JL. Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 1992; 44: 104-9
43. Altaras MM, Aviram R, Cohen I, et al. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993; 49: 255-8
44. Clarke MR. Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol 1993; 51: 411-5
45. Cuenca RE, Giuchino J, Arredondo MA, et al. Endometrial carcinoma associated with breast carcinoma. Cancer 1996; 77: 2058-63
46. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet 1995; 49: 241-57
47. Cohen I, Altaras MM, Shapira J, et al. Postmenopausal tamoxifen treatment and endometrial pathology. Obst Gynecol Surv 1994; 49: 823-9
48. Ross D, Whitehead M. Hormonal manipulation and gynaecological cancer: the tamoxifen dilemma. Curr Opin Obstet Gynecol 1995; 7: 63-8.
49. Vessey MP. Exogenous hormones in the aetiology of cancer in women. J R Soc Med 1984; 77: 542-9
50. Schwartzbaum JA, Hulka BS, Fowler WCJ, et al. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987; 126: 851-60
51. Silva E, Tornos C, Follen-Mitchell M. Malignant neoplasm of the uterine corpus in patients with breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 1994; 13: 248-58
52. Deligdisch L, Cohen CJ, Dottino P. Tamoxifen therapy and endometrial neoplasia. Eur J Cancer 1991; 27 Suppl. 2: 127
53. Segna RA, Dottino DR, Deligdisch L, et al. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992; 59: 416-8
54. Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with higher incidence of adverse histologic features. Gyncol Oncol 1994; 55: 164-8
55. De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 1991; 36 (2): 127-30
56. Neven P, De Muylder X, Van Belle Y, et al. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990; 35: 235-8
57. Cohen I, Rosen DJD, Shapiro J, et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993; 100: 567-70
58. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-4
59. Nuovo MA, Nuovo GJ, McCaffrey RM, et al. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989; 8: 125-31
60. Cohen I, Shapira Y, Altaras M, et al. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol 1992; 99: 773-4
61. Cohen I, Figer A, Altaras MM, et al. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestins. Int J Gynecol Pathol 1996; 15: 17-22
62. Ugwumado AHN, Bower D, Ho PK. Tamoxifen-induced adenomyosis and adenomyomatous endometrial polyp. Br J Obstet Gynaecol 1993; 100: 386-88
63. Corley D, Rowe J, Curtis MT, et al. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992; 79: 111-6
64. Ford MRW, Turner MJ, Wood C, et al. Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol 1988; 158: 119
65. Cano A, Matallin P, Legua V, et al. Tamoxifen and the uterus and endometrium. Lancet 1989; 1: 376
66. Le Bouedec G, Kauffman P, Pingeon JM. Postmenopausal endometriosis developed during tamoxifen treatment. Rev Fr Gynecol Obstet 1991; 86: 407-10
67. Cohen I, Altaras M, Lew S, et al. Ovarian endometroid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol Oncol 1994; 55: 443-7
68. Leo L, Lanza A, Re A, et al. Leiomyomas in patients receiving tamoxifen. Clin Exp Obstet Gynecol 1994; 2: 94-8
69. Cohen I, Beyth Y, Tepper R, et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 1995; 58: 86-91
70. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymtomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994; 52: 185-90
71. Kedar RP, Borne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-21
72. Gorodeski GI, Beery R, Lunenfeld B, et al. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil Steril 1992; 57: 320-7
73. Touraine P, Driques P, Cartier I, et al. Lack of induction of endometrial hyperplasia with tamoxifen. Lancet 1995; 345: 254-5
74. Cohen CJ, Rahaman J. Endometrial cancer. Cancer 1995; Suppl. 10; 76: 2044-52
75. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994; 47: 827-33
76. Sismondi P, Biglia N, Volpi E, et al. Tamoxifen and endometrial cancer. Am NY Acad Sci 1994; 734: 310-21
77. Goldstein SR, Nachtigall M, Snyder JR, et al. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163: 119-21
78. Granberg S, Wikland M, Karlsson B, et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47-53
79. Cohen I, Rosen DJD, Tepper R, et al. Ultrasonographic evaluation of the endometrium with correlation to endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993; 5: 275-80
80. Anteby E, Yagel S, Zacut D, et al. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 1992; 340: 433-4
81. Neven P, De Muylder X, Van Belle Y. Tamoxifen and the uterus and endometrium. Lancet 1989; 1: 375-6
82. Amy JJ, Van Liedekerke D. Gynaecological monitoring during tamoxifen therapy. Lancet 1995; 345: 253-4
83. Neven P, De Muylder X, Van Belle Y, et al. Tamoxifen and the uterus. BMJ 1994; 309: 1313-4
84. Achiron R, Lipitz S, Sivan E, et al. Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med 1995; 14: 685-8
85. Decensi A, Fontana V, Bruno S, et al. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996; 14: 434-0
86. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30: 1714-21
87. Bisset D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344: 1244
88. Borne TH, Lawton F, Leather A, et al. Use of intracavity saline instillation and transvaginal ultrasonography to detect tamoxifen-associated endometrial polyps. Ultrasound Obstet Gynecol 1994; 4: 73-5
89. Jordan VC. Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 1995 Feb: 208 (2): 144-9
90. Hirsimäki P, Hirsimäki Y, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver a study with two antiestrogens. Arch Toxicol 1993; 67: 49-54
91. Greaves P, Goonetilleke R, Nunn G, et al. Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993 Sep 1; 53: 3919-24
92. Williams GM, Iatropoulos MJ, Djordjevie MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 315-7
93. White IN, deMatteis F, Davis A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer 344/n rats. DBA/2 and C57BL/6 mice and human MCL-5 cells. Carcinogenesis 1992; 13: 2197-203
94. Carthew P, Martin EA, White IN, et al. Tamoxifen induces short-term cumulative DNA damage and liver tumours in rats: promotion by phenobarbital. Cancer Res 1995 Feb 1; 55 (3): 544-7
95. Fugh-Berman A, Epstein S. Tamoxifen: disease prevention or disease substitution? Lancet 1992 340: 1143-7
96. Wanless IR, Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest 1982 46 (3): 313-20
97. Edmonson HA, Reynolds TB, Henderson B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86: 180-2
98. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 1991; 20: 38-46
99. Sackett DL, Hayes RB, Tugwell P. Deciding whether your treatment has done harm. In: Sackett DL, Hayes RB, Tugwell P, editors. Clinical epidemiology: a basic science for clinical medicine. Boston: Little Brown & Co 1985; 223-4
100. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995 May 3; 87 (9): 645-51
101. Rutqvist LE, Cedermark B, Glas U, et al. The Stockholm Trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res Treat 1987; 10: 255-66
102. Rydén S, Möller T, Hafström LO, et al. Adjuvant therapy of breast cancer: compliance and data validity in a multi-center trial. Controlled Clin Trials 1986; 7: 290-305
103. Mouridsen HT, Rose C, Overgaard M, et al. Adjuvant treatment of postmenopausal patients with high risk breast cancer: results from the Danish adjuvant trial DBCG77C And DBCG82C. Acta Oncol 1988; 27: 699-705
104. Muhlemann K, Cook LS, Weiss NS. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 1994; 30: 201-4
105. Popper H, Selikoff IJ, Maltoni C, et al. Comparison of neoplastic hepatic lesions in man and experimental animals. In: Hiatt HH, Watson JD, Winsten JA, editors. Origins of human cancer book C: human risk assessment. New York: Cold Spring Harbor Laboratory, 1977: 1359-82
106. Hard GC, Iatrapoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Res 1993; 53: 4534-41
107. Iatropoulos M. Comparative histokinetic and xenodynamic considerations in toxicity. In: Welling PG, de la Iglesia FA, editors. Drug toxicokinetics. New York: Marcel Dekker, 1993: 245-66
108. Jordan VC. Tamoxifen and tumorigenicity a predictable concern. J Natl Cancer Inst 1995; 87: 623-6
109. Watanabe M, Tanaka H, Koizumi, et al. General toxicity stuies of tamoxifen in mice and rats. Jichuken Enriskokenjuoko 1980; 6: 1-36
110. Maltoni C, Pino C, Paladini G. Project of experimental bioassays on chemoprevention agents performed at the Bologna institute of Oncology: report on tamoxifen control of spontaneous mammary tumours in Sprague-Dawley rats. Cancer Invest 1988; 6: 643-58
111. Hirsimäki P, Hirsimäki Y, Nieminen L. The effects of tamoxifen citrate and toremifene citrate on the ultrastructure of the rat liver. Inst Phys Conf Ser 1988; 6: 643-58
112. Gau TC. Open letter concerning Nolvadex, 1987, Stuart Pharmaceuticals.
113. Metzler M, Schiffman D. Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene type antiestrogens. Am J Clin Oncol 1991; 14: S30-5
114. Han X, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992; 52: 1360-3
115. Mishkin SY, Farber E, Ho RK, et al. Evidence for the hormone dependency of malignant transformation after endogenous 17-beta estradiol and tamoxifen. Hepatology 1983; 3: 308-16
116. Kohigashi K, Fukada Y, Imura H. Inhibitory effect of tamoxifen on DES-promoted hepatic tumorigenesis in male rats and its possible mechanism of action. Gann 1988; 79: 1335-9
117. Taper HS. The effect of estradiol-17-phenylpropionate and estadiol benzoate on N-nitrosmorpholine-induced liver carcinogenesis in ovariectomized female rats. Cancer 1978; 42: 462-7
118. Vickers AE, Nelson K, McCoy Z, et al. Changes in estrogen receptor, DNA ploidy, and estrogen metabolism in rat hepatocytes during a two-stage model for hepatocarcinogenesis using 17-alfa- ethinylestradiol as the promoting agent. Cancer Res 1989; 49: 6512-20
119. Dragan YP, Fahey S, Street K, et al. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat 1994; 31 (1): 11-25
120. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen. Eur J Cancer 1994; 30A (11): 1714-21
121. Powles TJ, Hickish T. Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst 1995 Sep 20; 87 (18): 1343-45
122. Mani C, Kupfer D. Cytochrome P-450 mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver; possible involvement of flavin-containing mono-oxygenases in tamoxifen activation. Cancer Res 1991; 51: 6052-8
123. 32P postlabelling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 1994; 15: 2087-94
124. Pathak DN, Pongracz K, Bodell WJ. Microsomal and peroxidase activation of 4-hydroxytamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 1994; 16: 11-5
125. Pongracz K, Pathak DN, Nakamura T, et al. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res 1995; 55: 3012-5.
126. Taningher M, Saccomanno G, Santi L, et al. Quantitative predictability of carcinogenicity of the covalent binding index of chemical to DNA: comparison of the in vivo and in vitro assays. Environ Health Perspect 1990; 84: 183-92
127. Pathak GA, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 1994; 15: 529-32
128. Martin EA, Rick KJ, White IN. DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16: 1651-4
129. 32P postlabelled tamoxifen liver DNA adducts in rats, mice and breast cancer patients. The Toxicologist 1994; 14: 405
130. Potter GA, McCague R, Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 1994; 15: 439-42
131. Ioannides C, Parke DV. The cytochromes P448 - a unique family of enzymes involved in chemical toxicity and carcinogenesis. Biochem Pharmacol 1987; 36: 4197-207
132. Ahotupa M, Hirsimäki P. The effect of tamoxifen citrate and toremifen citrate on lipid peroxidation, antioxidant enzymes and xenobiotic metabolizing enzymes in rat liver. Vth International Congress of toxicology: 1989; Brighton, England
133. Ahotupa M, Hirsimäki P, Pärssinen R, et al. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis 1994; 15 (5): 863-8
134. Farber E. Cellular biochemistry of the stepwise development of cancer with chemicals: GHA Clowes Memorial lecture. Cancer Res 1984; 44: 5463-74
135. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1994 Jul 15; 54: 3864-7
136. Lullmann H, Lullmann-Rauch R. Tamoxifen-induced generalised lipidosis in rats subchronically treated with high doses. Toxicol Appl Pharmacol 1981; 61: 138-46
137. Simon R. Discovering the truth about tamoxifen: problems of multiplicity in statistical evaluation of biomedical data. J Natl Cancer Inst 1995 May 3; 87 (9): 6-8
138. CRC Adjuvant breast trial working party. Cyclofosfamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988; 57: 604-7
139. Ribeiro G, Swindell R. The Christie hospital adjuvant tamoxifen trial. Br J Cancer 1988; 57: 601-3
140. Teppo L, Pukkala E, Saxén E. Multiple cancer an epidemiologic exercise in Finland. J Natl Cancer Inst 1985; 75: 207-17
141. Harvey EB, Brinton LA. Second cancer following cancer of breast in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985; 68: 99-112
142. Ewertz M, Mouridsen HT. Second cancer following cancer of female breast in Denmark, 1943-1980. Natl Cancer Inst Monogr 1985; 68: 325-9
143. Furner SE, Davis FG, Nelson RL, et al. A case control study of large bowel cancer and hormone exposure in women. Cancer Res 1989; 49: 4936-40
144. Chute CG, Willett WC, Colditz GA, et al. A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Cancer Res 1989; 49: 4936-40
145. Gerhardsson de Verdier M, London S. Reproductive factors, exogenous female hormones and colorectal cancer by subsite. Cancer Causes Control 1992; 3: 355-60
146. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15
147. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995 Sep 20; 87 (18): 1359-64
148. Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991 July 17; 83 (14): 1013-7
149. Kaufman M, Jonat W, Albel U, et al. Adjuvant randomized trials of doxorubicin/ cyclofosfamide versus doxorubicin/ cyclofosfamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node positive breast cancer. J Clin Oncol 1993; 11: 454-60
150. Baum M, Houghton J, Riley D. Results of the Cancer Research Campaign adjuvant trial for perioperative cyclophosphamide and long-term tamoxifen in early breast cancer reported at the tenth year of follow-up. Acta Oncol 1992; 3: 251-7
151. Fischer B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989 Feb 23; 320: 479-84